OTCPicks.com Daily Market Movers Digest Midday Report for Monday, November 3rd PHFB, FBTX, ASTM, MEMY

Our Stocks to Watch today include Phantom Fiber Corp. (OTCBB: PHFB), Franklin Bank Corp. (Nasdaq: FBTX), Aastrom Biosciences Inc. (Nasdaq: ASTM) and Memory Pharmaceuticals Corp. (Nasdaq: MEMY).

PHANTOM FIBER CORPORATION (OTCBB: PHFB)

Phantom Fiber Corporation is a leading developer of wireless platform software that enables its customers to deliver high-performance applications across global communications networks to mobile users. The company's wireless platform extends the rich multimedia content and user experience of existing Internet web sites securely and instantly to over 1,500 mobile devices including cellular phones and PDAs. This platform is already deployed to most segments of the global gaming industry and can be used by enterprises seeking to implement high performance mobile applications in such markets as: remote video surveillance; banking and brokerage applications; as well as the logistics and distribution markets. Visit www.phantomfiber.com for more information about Phantom Fiber.

FRANKLIN BANK CORPORATION (NASDAQ: FBTX)

"Up 82.29% in morning trading"

Franklin, headquartered in Houston, Texas, was formed in April 2002. Franklin's common stock initiated trading on the Nasdaq Stock Market in December 2003 under the ticker symbol "FBTX." In May 2006, Franklin raised additional capital through an offering of its Series A Non-Cumulative Perpetual Preferred Stock that is now trading on The American Stock Exchange under the ticker symbol "FBK-P." Through the Bank, Franklin offers a wide variety of consumer and business products and services. The Bank focuses on providing high-quality personalized service through its trusted financial advisors and strives to meet all of the financial needs of its customers. In addition to various deposit and loan products, the Bank offers retail brokerage services through a third-party provider.

AASTROM BIOSCIENCE INCORPORATED (NASDAQ: ASTM)

"Up 38.80% in morning trading"

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Ongoing development activities are focused on applying TRC technology to cardiac and vascular tissue regeneration. The Company is currently focused on cardiovascular regeneration and is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial).

MEMORY PHARMACEUTICALS CORPORATION (NASDAQ: MEMY)

"Up 28.80% in morning trading"

Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer's disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company's products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer's disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzheimer's disease and CIAS. Its products also comprise PDE4 inhibitors, including MEM 1414, a phase I clinical trial program, as well as MEM 1917 for CNS disorders and depression; PDE10 Inhibitor program; and 5-HT6 Antagonists for the treatment of Alzheimer's disease, schizophrenia, attention deficit disorder, and obesity. The company has collaborations with F. Hoffman-La Roche, Ltd. for the development of nicotinic alpha-7 agonists; and Amgen, Inc. for the development of PDE10 inhibitors. In addition, it has a development agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was founded in 1997 and is based in Montvale, New Jersey.

About OTCPicks.com

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has been compensated two thousand dollars by a third party (Blue Wave Advisors) for PHFB advertising and promotional services.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.